

Cetuximab for the treatment of advanced non-small cell lung cancer
<http://www.nice.org.uk/Guidance/TA/Wave15/4>

Dear Consultees and Commentators,

This appraisal will be delayed due to ongoing regulatory discussions with regard to this license extension. The development programme is ongoing and further analysis of the data is expected. When this data is available we will reschedule the appraisal.

We expect to be able to provide you with an update in April. We will provide consultees with a new deadline for their statements at that time. (Consultees do not have to complete their statements by 23 March.)

Best wishes,

Jeremy

Jeremy Powell
Technology Appraisal Project Manager
National Institute for Health and Clinical Excellence
MidCity Place | 71 High Holborn | London WC1V 6NA | United Kingdom
Tel: 44 (0)20 7045 2248 | Fax: 44 (0)20 7061 9830